Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and Cynomolgus monkeys

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 1, 2003, Pages 93-99

  Lin, Chin Chung ^a   Luu, Trong ^a   Lourenco, David ^a   Yeh, Li Tain ^a   Lau, Johnson Y N ^a  

^a Ribapharm Inc   (United States)

Author keywords

Hepatitis C; Levovirin; Metabolism; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; DRUG METABOLITE; LEVOVIRIN; PEGATRON; PEGINTERFERON ALPHA2B; REBETRON; RIBAVIRIN; RIBAVIRIN DERIVATIVE; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG URINE LEVEL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MALE; MONKEY; NONHUMAN; RADIOACTIVITY; RAT; RAT STRAIN;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; FECES; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RIBAVIRIN; STEREOISOMERISM;

EID: 0037256819     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg046     Document Type: Article

References (15)

1. Sidwell, R. W., Huffman, J. H., Khare, G. P., Allen, L. B., Witkowski, J. T. & Robins, R. K. (1972). Broad-spectrum antiviral activity of Virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177, 705-6.
2. Stephen, E. L., Jones, D. E., Peters, E. C., Eddy, G. A., Loizeaux, P. S. & Jahrling, P. B. (1980). Ribavirin treatment of Toga-, Arena-, and Bunyavirus infections in subhuman primates and other laboratory animal species. In Ribavirin: A Broad Spectrum Antiviral Agent (Smith, R. A. & Kirkptrick, W., Eds), pp. 169-84. Academic Press, New York, NY, USA.
3. Streeter, D. G., Witkowski, J. T., Khare, G. P., Sidwell, R. W., Bauer, R. J., Robins, R. K. et al. (1973). Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proceedings of the National Academy of Sciences, USA 70, 1174-8.
4. Tam, R. C., Pai, B. P., Bard, J., Lim, C., Averett, D. R., Phan, U. T. et al. (1999). Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. Journal of Hepatology 30, 376-82.
5. Tam, R. C., Lim, C., Bard, J. & Pai, B. (1999). Contact hypersensitivity responses following ribavirin treatment in vivo are influenced by Type 1 cytokine polarization, regulation of IL-10 expression, and costimulatory signaling. Journal of Immunology 163, 3709-17.
6. Tam, R. C., Ramasamy, K., Bard, J., Pai, B., Lim, C. & Averett, D. R. (2000). The ribavirin analogue ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrobial Agents and Chemotherapy 44, 1276-83.
7. Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y., Hong, Z. et al. (2000). The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Medicine 6, 1375-9.
8. McHutchison, G., Gordon, S. C., Schiff, E. R., Mitchell, M. D., Shiffmann, M. L., Lee, W. M. et al. (1998). Interferon alpha 2B alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 339, 1485-92.
9. 14C-Ribavirin: distribution and pharmacokinetic studies in rats, baboon and man. In Ribavirin: A Broad Spectrum Antiviral Agent (Smith, R. A. & Kirkpatrick, W., Eds), pp. 83-98. Academic Press, New York, NY, USA.
10. Lortora, J. J., Rege, A. B., Acour, J. T., Ferencz, N., George, W. J., VanDyke, R. B. et al. (1991). Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 50, 442-9.
11. Page, T. & Conner, J. D. (1990). The metabolism of ribavirin in erythrocytes and nucleated cells. Biochemistry International 22, 379-83.
12. Shulman, N. R. (1984). Assessment of hematological effects of ribavirin in humans. In Clinical Application of Ribavirin (Smith, R. A., Knight, V. & Smith, J. A. D., Eds), pp. 79-92. Academic Press, New York, NY, USA.
13. Ramasamy, K., Tam, R., Bend, J. & Averett, D. R. (2000). Monocyclic L-nucleoside with type 1 cytokine inducing activity. Journal of Medicinal Chemistry 43, 1019-28.
14. Corritori, S., Lau, J. Y. N. & Lin, C. C. (2001). Safety studies of levovirin, a second generation ribavirin, showed excellent safety profile. Hepatology 34, 219A (abstract 181).
15. +-nucleoside purine (N1) transporter. Pharmaceutical Research 15, 950-2.